Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Gains from Sales and Divestitures: 2017-2019

Historic Gains from Sales and Divestitures for Summit Therapeutics (SMMT) over the last 1 years, with Mar 2019 value amounting to $0.01.

  • Summit Therapeutics' Gains from Sales and Divestitures was N/A to $0.01 in Q1 2019 from the same period last year, while for Mar 2019 it was $0.01, marking a year-over-year change of. This contributed to the annual value of -$500,453 for FY2017, which is N/A change from last year.
  • According to the latest figures from Q1 2019, Summit Therapeutics' Gains from Sales and Divestitures is $0.01, which was up 100.00% from -$458,437 recorded in Q4 2017.
  • In the past 5 years, Summit Therapeutics' Gains from Sales and Divestitures ranged from a high of $0.01 in Q1 2019 and a low of -$463,934 during Q1 2017.
  • Moreover, its 2-year median value for Gains from Sales and Divestitures was -$46,572 (2017), whereas its average is -$197,949.